By Fineline Cube Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its in-house developed isophane protamine recombinant human insulin mix (30R) prefilled formulation has received marketing approval from China’s National Medical Products Administration (NMPA). This approval marks a significant milestone in the company’s diabetes care portfolio.
Product Profile & Clinical Value
| Feature | Detail |
|---|---|
| Product Name | Isophane Protamine Recombinant Human Insulin Mix (30R) |
| Formulation | Prefilled pen for convenient administration |
| Composition | Classic 30/70 premix: 30% soluble human insulin (short-acting) + 70% isophane protamine human insulin (intermediate-acting) |
| Primary Benefit | Simplifies treatment regimens by reducing the need for patients to manually mix separate short- and intermediate-acting insulins. |
| Patient Impact | Aims to enable more stable blood glucose control and improve quality of life for people with diabetes requiring basal-bolus therapy. |
Strategic Significance
The Chinese diabetes market, with over 140 million patients, represents one of the largest global opportunities for insulin therapies. Sunshine Lake’s approval of its own prefilled 30R insulin allows it to compete directly in the established premixed insulin segment, a mainstay of treatment for many patients.
By offering a domestically developed, convenient, and clinically validated option, Sunshine Lake strengthens its position as a key player in China’s biopharmaceutical landscape. The prefilled pen format addresses a clear unmet need for user-friendly devices that enhance adherence and simplify daily management for patients and caregivers alike.
This launch provides a capital-efficient revenue stream and establishes a foundational product upon which the company can build a broader diabetes franchise.
Forward-Looking Statements
This brief contains forward-looking statements regarding the commercial success of the new insulin product. Actual sales will be influenced by market access, pricing, reimbursement, and competitive dynamics within the mature insulin market.-Fineline Info & Tech